News & ViewsNewslettersContactBecome a Research Patient
DHRHealth Institute for Research and Development

Clinical Trial

A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY)

Study Status:

Not Yet Recruiting

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose:

Purpose is to determine if “MEDI8897” will prevent medically attended Respiratory syncytial virus (RSV) in healthy infants entering their first RSV season.

Information: 

Principal Investigator
Dynio Honrubia, MD
Sponsor
MedImmune LLC
Type of Trial
Interventional
DHRHealth Institute for Research and Development
5323 S. McColl Rd., Edinburg, TX 78539
(956) 362-2390
© 2022 DHR Health Institute for Research & Development | All Rights Reserved | Terms & Conditions | Site By: KangoMedia
chevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram